Inari Medical, Inc. (NARI)
NASDAQ: NARI · IEX Real-Time Price · USD
38.07
-0.11 (-0.29%)
At close: Apr 25, 2024, 4:00 PM
38.06
-0.01 (-0.03%)
After-hours: Apr 25, 2024, 5:02 PM EDT
Inari Medical Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Inari Medical stock have an average target of 69.33, with a low estimate of 52 and a high estimate of 83. The average target predicts an increase of 82.11% from the current stock price of 38.07.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Inari Medical stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Buy | 3 | 3 | 3 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $75 | Strong Buy | Maintains | $75 | +97.01% | Apr 12, 2024 |
| Truist Securities | Truist Securities | Hold Maintains $61 → $52 | Hold | Maintains | $61 → $52 | +36.59% | Mar 22, 2024 |
| Needham | Needham | Strong Buy Reiterates $72 | Strong Buy | Reiterates | $72 | +89.13% | Mar 6, 2024 |
| Needham | Needham | Strong Buy Reiterates $72 | Strong Buy | Reiterates | $72 | +89.13% | Feb 29, 2024 |
| Truist Securities | Truist Securities | Hold Reiterates $63 → $61 | Hold | Reiterates | $63 → $61 | +60.23% | Feb 29, 2024 |
Financial Forecast
Revenue This Year
600.12M
from 493.63M
Increased by 21.57%
Revenue Next Year
708.81M
from 600.12M
Increased by 18.11%
EPS This Year
-0.56
from -0.03
EPS Next Year
0.21
from -0.56
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 621.9M | 744.5M | 880.2M | 1.1B |
| Avg | 600.1M | 708.8M | 830.4M | 1.0B |
| Low | 573.2M | 669.9M | 774.0M | 903.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 26.0% | 24.1% | 24.2% | 37.3% |
| Avg | 21.6% | 18.1% | 17.2% | 23.3% |
| Low | 16.1% | 11.6% | 9.2% | 8.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -0.13 | 0.89 | 1.47 | 1.72 |
| Avg | -0.56 | 0.21 | 0.63 | 1.25 |
| Low | -0.93 | -0.11 | 0.32 | 0.80 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | 616.6% | 171.7% |
| Avg | - | - | 209.0% | 97.9% |
| Low | - | - | 57.7% | 26.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.